rs4770433

Variant summary

Our verdict is Benign. The variant received -18 ACMG points: 0P and 18B. BP4_ModerateBP6_Very_StrongBA1

The NM_014363.6(SACS):​c.*484T>C variant causes a 3 prime UTR change. The variant allele was found at a frequency of 0.41 in 525,070 control chromosomes in the GnomAD database, including 46,198 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.37 ( 11482 hom., cov: 32)
Exomes 𝑓: 0.43 ( 34716 hom. )

Consequence

SACS
NM_014363.6 3_prime_UTR

Scores

2

Clinical Significance

Likely benign criteria provided, multiple submitters, no conflicts B:4

Conservation

PhyloP100: 4.44

Publications

20 publications found
Variant links:
Genes affected
SACS (HGNC:10519): (sacsin molecular chaperone) This gene encodes the sacsin protein, which includes a UbL domain at the N-terminus, a DnaJ domain, and a HEPN domain at the C-terminus. The gene is highly expressed in the central nervous system, also found in skin, skeletal muscles and at low levels in the pancreas. This gene includes a very large exon spanning more than 12.8 kb. Mutations in this gene result in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), a neurodegenerative disorder characterized by early-onset cerebellar ataxia with spasticity and peripheral neuropathy. The authors of a publication on the effects of siRNA-mediated sacsin knockdown concluded that sacsin protects against mutant ataxin-1 and suggest that "the large multi-domain sacsin protein is able to recruit Hsp70 chaperone action and has the potential to regulate the effects of other ataxia proteins" (Parfitt et al., PubMed: 19208651). A pseudogene associated with this gene is located on chromosome 11. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, May 2013]
SACS Gene-Disease associations (from GenCC):
  • Charlevoix-Saguenay spastic ataxia
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, G2P, Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae), Myriad Women’s Health

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -18 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.27).
BP6
Variant 13-23329652-A-G is Benign according to our data. Variant chr13-23329652-A-G is described in ClinVar as Likely_benign. ClinVar VariationId is 311495.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.442 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SACSNM_014363.6 linkc.*484T>C 3_prime_UTR_variant Exon 10 of 10 ENST00000382292.9 NP_055178.3 Q9NZJ4-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SACSENST00000382292.9 linkc.*484T>C 3_prime_UTR_variant Exon 10 of 10 5 NM_014363.6 ENSP00000371729.3 Q9NZJ4-1

Frequencies

GnomAD3 genomes
AF:
0.371
AC:
56412
AN:
151946
Hom.:
11478
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.197
Gnomad AMI
AF:
0.612
Gnomad AMR
AF:
0.418
Gnomad ASJ
AF:
0.377
Gnomad EAS
AF:
0.395
Gnomad SAS
AF:
0.398
Gnomad FIN
AF:
0.463
Gnomad MID
AF:
0.329
Gnomad NFE
AF:
0.446
Gnomad OTH
AF:
0.374
GnomAD4 exome
AF:
0.426
AC:
158810
AN:
373008
Hom.:
34716
Cov.:
0
AF XY:
0.424
AC XY:
82746
AN XY:
195146
show subpopulations
African (AFR)
AF:
0.187
AC:
1768
AN:
9444
American (AMR)
AF:
0.439
AC:
5052
AN:
11508
Ashkenazi Jewish (ASJ)
AF:
0.376
AC:
4547
AN:
12086
East Asian (EAS)
AF:
0.411
AC:
11061
AN:
26900
South Asian (SAS)
AF:
0.392
AC:
10625
AN:
27122
European-Finnish (FIN)
AF:
0.445
AC:
12190
AN:
27402
Middle Eastern (MID)
AF:
0.358
AC:
640
AN:
1786
European-Non Finnish (NFE)
AF:
0.442
AC:
103488
AN:
234184
Other (OTH)
AF:
0.418
AC:
9439
AN:
22576
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
4166
8332
12497
16663
20829
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
468
936
1404
1872
2340
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.371
AC:
56424
AN:
152062
Hom.:
11482
Cov.:
32
AF XY:
0.375
AC XY:
27840
AN XY:
74328
show subpopulations
African (AFR)
AF:
0.196
AC:
8149
AN:
41530
American (AMR)
AF:
0.418
AC:
6388
AN:
15276
Ashkenazi Jewish (ASJ)
AF:
0.377
AC:
1305
AN:
3466
East Asian (EAS)
AF:
0.395
AC:
2046
AN:
5174
South Asian (SAS)
AF:
0.398
AC:
1914
AN:
4814
European-Finnish (FIN)
AF:
0.463
AC:
4891
AN:
10558
Middle Eastern (MID)
AF:
0.330
AC:
97
AN:
294
European-Non Finnish (NFE)
AF:
0.446
AC:
30280
AN:
67926
Other (OTH)
AF:
0.377
AC:
796
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.499
Heterozygous variant carriers
0
1719
3438
5158
6877
8596
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
546
1092
1638
2184
2730
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.418
Hom.:
59321
Bravo
AF:
0.359
Asia WGS
AF:
0.416
AC:
1446
AN:
3476

ClinVar

Significance: Likely benign
Submissions summary: Benign:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Limb-girdle muscular dystrophy, recessive Benign:1
Jun 14, 2016
Illumina Laboratory Services, Illumina
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Autosomal recessive limb-girdle muscular dystrophy type 2C Benign:1
Jun 14, 2016
Illumina Laboratory Services, Illumina
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:1
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Charlevoix-Saguenay spastic ataxia Benign:1
Jun 14, 2016
Illumina Laboratory Services, Illumina
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.27
CADD
Benign
14
DANN
Benign
0.85
PhyloP100
4.4
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs4770433; hg19: chr13-23903791; API